| 1. |
Keeping cost-utility and clinical trial results together ideal |
| |
PharmacoEconomics & Outcomes News,
Volume &NA;,
Issue 456,
2004,
Page 2-2
&NA;,
Preview
|
|
ISSN:1173-5503
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 2. |
Insulin analogues worth the extra cost in type 1 DM |
| |
PharmacoEconomics & Outcomes News,
Volume &NA;,
Issue 456,
2004,
Page 3-4
L Everitt,
Preview
|
|
摘要:
Type 1 diabetes mellitus (DM) imposes a heavy toll on society, due to its high prevalence and mortality, and the acute and chronic complications associated with it. At the 64th annual scientific sessions of the American Diabetes Association (ADA) [Orlando, Florida, US; Jun 2004], a team of researchers from Switzerland and Denmark showed that although insulin detemir plus insulin aspart cost more than NPH insulin [insulin suspension isophane] plus soluble human insulin in patients with type 1 DM, glycaemic control improved and there was a reduction in hypoglycaemic events and body mass index (BMI) among recipients of the former therapy.1A second study presented at the conference by investigators from the US and Spain revealed that the insulin analogue insulin glargine was also good value for money compared with NPH insulin.2
ISSN:1173-5503
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 3. |
A new set of clinical practice guidelines for the treatment of patients with prostate cancer have been developed by the American Society of Clinical Oncology |
| |
PharmacoEconomics & Outcomes News,
Volume &NA;,
Issue 456,
2004,
Page 4-4
&NA;,
Preview
|
|
ISSN:1173-5503
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 4. |
Grading system enhances confidence in guidelines |
| |
PharmacoEconomics & Outcomes News,
Volume &NA;,
Issue 456,
2004,
Page 5-5
&NA;,
Preview
|
|
ISSN:1173-5503
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 5. |
Management of early RA varies in France |
| |
PharmacoEconomics & Outcomes News,
Volume &NA;,
Issue 456,
2004,
Page 6-6
&NA;,
Preview
|
|
ISSN:1173-5503
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 6. |
According to current guidelines, treatment and control rates of hypertension among elderly adults are suboptimal, |
| |
PharmacoEconomics & Outcomes News,
Volume &NA;,
Issue 456,
2004,
Page 7-7
&NA;,
Preview
|
|
ISSN:1173-5503
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 7. |
Patients' nonadherence to antipsychotic medication appears to exhibit a consistent association with greater costs, |
| |
PharmacoEconomics & Outcomes News,
Volume &NA;,
Issue 456,
2004,
Page 8-8
&NA;,
Preview
|
|
ISSN:1173-5503
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 8. |
Value of donepezil doubtful in Alzheimer's disease |
| |
PharmacoEconomics & Outcomes News,
Volume &NA;,
Issue 456,
2004,
Page 9-9
&NA;,
Preview
|
|
ISSN:1173-5503
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 9. |
Valsartan cost effective in HF? |
| |
PharmacoEconomics & Outcomes News,
Volume &NA;,
Issue 456,
2004,
Page 10-10
&NA;,
Preview
|
|
ISSN:1173-5503
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 10. |
Peak sales of $US250−400 million are expected by Serono for its psoriasis agent efalizumab |
| |
PharmacoEconomics & Outcomes News,
Volume &NA;,
Issue 456,
2004,
Page 11-11
&NA;,
Preview
|
|
ISSN:1173-5503
出版商:ADIS
年代:2004
数据来源: ADIS
|
首页
